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Abstract
Previous evidence from tooth agenesis studies suggested IRF6 and TGFA interact. Since tooth agenesis is commonly found
in individuals with cleft lip/palate (CL/P), we used four large cohorts to evaluate if IRF6 and TGFA interaction contributes to
CL/P. Markers within and flanking IRF6 and TGFA genes were tested using Taqman or SYBR green chemistries for case-
control analyses in 1,000 Brazilian individuals. We looked for evidence of gene-gene interaction between IRF6 and TGFA by
testing if markers associated with CL/P were overtransmitted together in the case-control Brazilian dataset and in the
additional family datasets. Genotypes for an additional 142 case-parent trios from South America drawn from the Latin
American Collaborative Study of Congenital Malformations (ECLAMC), 154 cases from Latvia, and 8,717 individuals from
several cohorts were available for replication of tests for interaction. Tgfa and Irf6 expression at critical stages during
palatogenesis was analyzed in wild type and Irf6 knockout mice. Markers in and near IRF6 and TGFA were associated with
CL/P in the Brazilian cohort (p,1026). IRF6 was also associated with cleft palate (CP) with impaction of permanent teeth
(p,1026). Statistical evidence of interaction between IRF6 and TGFA was found in all data sets (p = 0.013 for Brazilians;
p = 0.046 for ECLAMC; p = 1026 for Latvians, and p = 0.003 for the 8,717 individuals). Tgfa was not expressed in the palatal
tissues of Irf6 knockout mice. IRF6 and TGFA contribute to subsets of CL/P with specific dental anomalies. Moreover, this
potential IRF6-TGFA interaction may account for as much as 1% to 10% of CL/P cases. The Irf6-knockout model further
supports the evidence of IRF6-TGFA interaction found in humans.
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Introduction
Oral-facial clefts are common birth defects with an incidence of
1–2 in 1000 live births, thus comprising almost one-half of all
craniofacial anomalies. They impose adverse health, social, and
economic implications for the affected individuals and their
families [1]. Although the mortality and morbidity of an infant
born with a cleft lip and or a cleft palate has improved greatly in
the last century, it is still elevated for infants born with multiple
additional anomalies. Among the consequences of being born with
clefts are shorter life span and increased risk for all major causes of
death when compared to individuals without clefts [2].
Cleft lip with or without cleft palate (herein called cleft lip/
palate) can be classified as nonsyndromic or syndromic based on
the presence of other associated congenital defects. Approximately
20–50% of all cleft cases are associated with one of more than 400
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syndromes [3]. Syndromic forms usually present Mendelian
inheritance patterns, which allow identification of causal genes.
Nonsyndromic cleft lip/palate however, is considered a genetically
complex trait with no clearly recognizable inheritance pattern [4].
Identifying the key genes responsible for the genesis of cleft lip/
palate is fundamental for elucidating the pathogenetic mechanisms
and developing measures for its management and prevention.
Studies have estimated that 3–14 genes interacting multiplicatively
may be involved in the etiology of cleft lip/palate [5], and a variety
of genes have been associated and suggested to play a role in the
genetic susceptibility to cleft lip/palate [4].
To date, the most consistent finding for the genetic etiology of
nonsyndromic cleft lip/palate has been the association of the
interferon regulatory factor 6 (IRF6) gene at 1q32 [6], previously
identified as etiologic for Van der Woude syndrome which
includes cleft lip/palate as part of the clinical spectrum [7]. A
particularly strong overtransmission of the ancestral allele V at a
V274I polymorphism (rs2235371) was detected in individuals of
Asian and South American ancestry from 8,003 individuals
representing ten distinct populations. Attributable risk calculations
suggested IRF6 could contribute to as much as 12% of all cleft
cases [6]. Intriguingly, additional studies with different populations
have consistently shown positive association between markers in
IRF6 and cleft lip/palate [8–22]. The frequency of the V274I risk
allele is over 97% in European and African populations making it
an unlikely candidate for the etiological mutation.
The association of the transforming growth factor alpha (TGFA)
gene at 2p13 with cleft lip/palate has also rendered intriguing
results. TGFA was the first gene associated to nonsyndromic cleft
lip/palate in a case-control study [23]. Several studies followed
with rather discrepant results; in turn, comparison among studies
with TGFA has been somewhat difficult due to unaccounted
variations in study design, markers tested and percentages of
patients with positive family history [24]. Meta-analytic approach-
es [25,26] concluded that TGFA plays a small but significant role
in cleft lip/palate with odds ratios indicating a modest effect size.
Instead of an effector gene, TGFA has been regarded as a]modifier
to the clefting phenotype [24].
Evidence from tooth agenesis studies suggested that IRF6 and
TGFA genes may interact [27,28]. Tooth agenesis is a common
congenital anomaly where one or more permanent teeth are
absent and is a frequent observation in individuals with cleft lip/
palate. Therefore interaction between IRF6 and TGFA in tooth
agenesis may also be relevant to cleft lip/palate. Since tooth
agenesis is commonly found in individuals with cleft lip/palate, we
used three large samples of cleft cases to test for interaction
between IRF6 and TGFA in the etiology of the cleft phenotype.
Results
Results of Case-control Comparisons
Tables 1 and 2 summarize the studied Brazilian samples and
genetic markers. There were no evidences of deviation from
Hardy-Weinberg equilibrium for any of the markers in cases and
controls (data not shown). Table 3 summarizes the linkage
disequilibrium relationships of the markers studied.
Table 4 summarizes the results of the association analysis
obtained for Brazilian Caucasian cases (N = 406) and controls
(N = 285) for each marker studied, according to each cleft
subphenotype. When comparing Brazilian cleft cases with
controls, we observed an association between the intronic marker
rs2902345 with cleft lip/palate (P,0.001). For IRF6, we found
significant association between the V274I polymorphism
(rs2235371) with complete left cleft lip/palate (P,0.001). An
intronic marker in IRF6 (rs2073487) also showed a trend for
association with complete left cleft lip/palate (P = 0.0009).
We also compared cleft subphenotypes with tooth agenesis and
other dental anomalies and controls. Table 5 summarizes the
results of the association analysis obtained in the Brazilian cases
(N = 406) and controls (N = 285) for TGFA and IRF6 markers,
according to each cleft subphenotype with dental anomalies.
Although genotype/allele frequencies did not significantly differ
between cases presenting with tooth agenesis and controls, we
found an association between the V274I marker in IRF6 and cleft
palate in the presence of impaction of permanent teeth
(P,0.0001).
Results of Attributable Fraction Calculations for IRF6-
TGFA Interaction
We calculated the attributable fraction (AF) for the high-risk
alleles at IRF6 V274I and TGFA C3827T (P = 0.03) for the
Brazilian sample, and the estimated contribution of the interaction
between these two genes in this population was found to be
approximately 1% (Table 6).
We also tested for IRF6-TGFA interaction in the ECLAMC
samples by observing the transmission of the high-risk alleles at
IRF6 V274I and TGFA C3827T in the 142 case-parent trios and
detected significant overtransmission of these alleles to the affect
child (P = 0.001). The attributable fraction for these samples
(AF = 0.04) suggests this interaction may account for ,4% of the
cases of cleft lip/palate in this particular population. Genotypes
used for these calculations are included as Supplemental Material
(Table S1).
Analysis of genotypes in additional 7,047 people from seven
distinct populations provides suggestive evidence of interaction
between two TGFA markers (rs3732253 and rs377122) with a
polymorphism in IRF6 (rs2013162) among Caucasians (P = 0.02)
and Asians (P = 0.03) (although these p-values are nominal and
would not be significant under strict Bonferroni correction).
Analysis of the pooled samples indicates statistical interaction
between a marker at TGFA (rs1807968) and another marker at
IRF6 (rs2013162) in the cleft lip only group (P = 0.003) (Table 7).
Attributable fraction calculations (AF = 0.10) further suggest
,10% of cleft lip cases may be attributed to such interaction in
the general population.
Table 1. Baseline clinical characteristics of the Brazilian
population.
Populations Cleft Control
N % N %
Age
Range 4–59 – 4–94 –
Mean 17.32 – 36.8 –
Gender
Males 302 60 165 33
Females 198 40 335 67
Race
Caucasian 406 82 285 58.2
African 79 16 38 7.8
Asian 9 2 167 34
Unknown 6 16 10 18
doi:10.1371/journal.pone.0045441.t001
IRF6-TGFA Interaction and Clefts
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We used genotypes for 154 cases from Latvia and genotype
frequencies from the HapMap Project as a replication panel for
this interaction between TGFA marker rs3732253 and IRF6
rs2013162. The results also suggest IRF6 and TGFA may
interactively contribute to the risk for having an affected child
(Table 8). The attributable fraction for these samples (AF = 0.04)
suggests such interaction may account for,4% of the cases of cleft
lip/palate in this particular population.
Results of Gene Expression Analysis
We investigated localization of Tgfa and Irf6 in wild type and
Irf6-null mice at critical stages during palate development. We
observed similar expression patterns for Tgfa and Irf6 in wild-type
mouse craniofacial tissues at embryonic days E13 through E15.
Positive immunoreactivity was observed in both epithelial and
mesenchymal tissues of the mouth and nasal cavities. Expression
was also detected in the brain. At day E14.5, when palatal fusion
takes place, both epithelial and mesenchymal cells in the palate
Table 2. Details of the SNPs investigated in this study.
SNP marker Base Positiona Approximate Llocation Function
Base
Change
Average
Heterozygozity Type of Assay
IRF6
rs4844880 207,937,539 90 kb 39 of IRF6 intron AT 0.488+/20.075 Taqman ODb
rs2235371 (V274I) 208,030,703 In IRF6 missense CT 0.247+/20.250 Taqman ODb
rs2013162 208,035,307 In IRF6 coding-synonymous AC 0.478+/20.102 Taqman ODb
rs861019 208,042,009 In IRF6 59UTR AG 0.474+/20.111 Taqman ODb
rs2073487 208,043,269 In IRF6 intron CT 0.479+/20.099 Taqman ODb
rs658860 208,057,172 11 kb 59 of IRF6 unknown CT 0.290+/20.247 Taqman ODb
TGFA
rs1058213 (C3827T) 70,530,971 In TGFA 39UTR CT 0.286+/20.247 Kinetic PCR
rs2166975 (C3296T) 70,531,502 In TGFA coding-synonymous GA 0.340+/20.233 Kinetic PCR
rs930655 70,537,959 In TGFA intron AG 0.438+/20.166 Taqman ODb
rs1523305 70,552,364 In TGFA intron CT 0.497+/20.038 Taqman ODb
rs2902345 70,570,107 In TGFA intron CT 0.471+/20.118 Taqman ODb
rs377122 70,620,533 In TGFA intron CT 0.485+/20.085 Taqman ODb
aAccording to the USCS Genome Browser on Human March 2006 Assembly (hg18).
bAssay-on-demand.
doi:10.1371/journal.pone.0045441.t002
Table 3. Results of linkage disequilibrium analyses for the investigated markers in the Brazilian Caucasian population (406 cases
and 285 controls).
Markers rs4844880 rs2235371 rs2013162 rs861019 rs2073487 rs658860
IRF6
rs4844880 – 0.057 0.009 0.011 0.009 0.006
rs2235371 0.538 – 0.091 0.005 0.093 0.007
rs2013162 0.221 0.858 – 0.070 0.986 0.090
rs861019 0.190 0.309 0.385 – 0.066 0.030
rs2073487 0.223 0.860 1.000 0.375 – 0.095
rs658860 0.097 0.677 0.873 0.404 0.903 –
rs1058213 rs2166975 rs930655 rs1523305 rs2902345 rs377122
TGFA
rs1058213 – 0.043 0.017 0.024 0.018 0.0001
rs2166975 0.434 – 0.032 0.036 0.031 0.002
rs930655 0.536 0.450 – 0.223 0.232 0.008
rs1523305 0.742 0.413 0.536 – 0.741 0.018
rs2902345 0.712 0.420 0.494 0.954 – 0.015
rs377122 0.065 0.074 0.092 0.160 0.160 –
r2 is above the diagonal; D’ is below the diagonal.
doi:10.1371/journal.pone.0045441.t003
IRF6-TGFA Interaction and Clefts
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were intensely stained for Tgfa and Irf6 (Figure 1). In Irf6 knockout
mice, however, we did not see Tgfa expression at E14.5 (Figure 2).
Discussion
Of all the genetic studies with cleft lip/palate, the association
with IRF6 is certainly the most consistent [6], and has been
consistently replicated in multiple populations [8–22]. IRF6
belongs to a gene family (IRFs) of transcription factors that
regulate expression of interferons-a and –b after viral infections,
and is a causal gene for Van der Woude’s syndrome which
includes cleft lip/palate, pits on the lower lip, and tooth agenesis as
part of the clinical phenotype [7]. Although the exact function of
this gene remains unknown, polymorphisms in IRF6 may account
for ,12% of all cleft cases in the background of other genes, with
an association of a particular V274I allele with isolated cleft lip/
palate among Filipinos [6].
Efforts are being made to unravel the specific role of IRF6 in
cleft lip/palate. Although direct sequencing of the coding regions
of IRF6 did not detect potential causative mutations, the causative
variant(s) could be in linkage disequilibrium with V274I but reside
in the regulatory element(s) of IRF6 [32]. An additional possibility
is that the V274I variant may be in linkage disequilibrium with a
marker in another gene and such interaction might influence
development of CL/P.
For many of the other genes previously associated with cleft lip/
palate, including TGFA, a variety of positive and negative results
have been reported, and TGFA has been largely ignored in the
recent years. TGFA was the first gene associated to isolated cleft
lip/palate in a case-control study [13] and was selected as a
candidate gene because of its expression on palatal tissue in culture
and its presence at high levels in the medial epithelial edge of the
palatal shelves at the time of palatal fusion [42]. More recently,
evidence of an excess of maternal transmission and possible
interactions with maternal exposures to cigarette smoking, alcohol
consumption and vitamin supplementation have been suggested to
underlie the influence of TGFA in human clefting [43].
For this study, we used a collection of 1000 samples from cleft
and control individuals from the Southeast region of Brazil [29].
Although the majority of residents of this region are descendants of
Portuguese who migrated during the colonization years of Brazil,
there is a substantial level of admixture confounding due to
population stratification. To avoid biased results due to population
stratification, the reported results reflect the analyses with
individuals of self-reported Caucasian ethnicity only.
Markers located within and flanking the IRF6 and TGFA genes
were tested for association with cleft of the lip or palate under a
case-control design. We found an association between a single
nucleotide polymorphism in the intron of the TGFA gene with cleft
lip/palate. There is no evidence suggesting this intronic variant is
etiologic, however introns seem to affect virtually any step of
mRNA maturation, including transcription initiation, transcrip-
tion elongation, transcription termination, polydenylation, nuclear
export, and mRNA stability [44]. Rs2902345 can potentially affect
transcription, and is coincidently located flanking a region we
suggested involved in segmental uniparental isodisomy in a case of
maxillary lateral incisor and mandibular second premolar agenesis
[45].
For IRF6, we found a positive association between the V274I
polymorphism and complete left cleft lip/palate. In contrast to
other studies [6,8–22], all of which showed association of IRF6
comparing only the three major cleft categories (cleft lip, cleft lip/
palate and cleft palate), we only found positive association when
comparing cleft subphenotypes with controls. Maybe IRF6 is not a
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strong risk factor for clefting in Brazil, or maybe it has specific
contributions, e.g. controlling the side of unilateral cleft. We also
found an association between the V274I polymorphism with cases
of cleft palate with impaction of permanent teeth. Tooth
impaction occurs when, for some reason, the permanent teeth
do not erupt and remain inside the alveolar bone. The reported
prevalence in the general population is about 1 to 2.5%, and it has
also been reported in children with clefts [46].
The frequency of the V274I polymorphism varies greatly
depending on geographic origin [6]. For instance, rs642961 was
found to be more useful in studies with populations of European
origin, since V274I frequency in these groups is remarkably low
[32]. But even this marker has distinct frequencies even
populations originating from north Europe are compare with
groups coming from the south (i.e., Hispanics versus non-
Hispanics) [47]. Although rs642961 is located at a site suggested
to be an AP-2a binding site promoter, we studied V274I in the
Brazilians due to the expected allele frequency differences.
Evidence however suggest that there is a contribution to cleft
susceptibility at the IRF6 locus but multiple genetic variants, rather
than a single one, may have etiological roles in this defect [47,48].
A common type of dental anomaly, tooth agenesis, has also
been reported in association with this same IRF6 variant by our
group [28,49]. Tooth agenesis is a common congenital anomaly
where one or more permanent teeth are absent and a frequent
observation in individuals with cleft lip/palate [29]. Previous
evidence from tooth agenesis studies suggested IRF6 and TGFA
genes may interact [28]. Therefore, we hypothesized interaction
between IRF6 and TGFA may also be relevant to cleft lip/palate.
We speculated on the attributable fraction for the interaction of
IRF6 and TGFA genes to the risk of cleft lip/palate using the
Brazilian case-control sample and three additional family or case
series data sets comprising a total of 8,717 individuals. We found
statistical evidence of gene-gene interaction in all of these data sets
and estimate such interaction could contribute from 1 percent to
as much as 10 percent of cleft cases. These findings are in
accordance with Zucchero et al. [6] who reported an attributable
risk of cleft lip or palate of about 12 percent for IRF6. Those
authors further stated the risk of recurrence is 9 percent among
siblings in families with a history of cleft lip/palate where the child
could have inherited the common risk allele. Taken together, these
findings suggest individual IRF6 status may be an important tool to
revisit recurrence risk estimates for cleft lip/palate.
Our expression assays showed Tgfa and Irf6 expression patterns
are similar at critical stages for mouse palate development.
However, Tgfa was not expressed in Irf6 knock out mice, which
suggests that Tgfa and Irf6 may share common pathways and Tgfa
may ultimately depend upon the Irf6 expression status. Mice
deficient for Irf6 have abnormal skin, limb and craniofacial
development, resultant from a primary defect in keratinocyte
differentiation and proliferation. Furthermore, mice homozygous
for the Irf6 null allele have a cleft palate which seems to be caused
by a defect in elevation, either as a primary defect or secondary to
crowding of the craniofacial structures owing to the constrictive
action of the skin or oral adhesions [40]. Deficiency of Tgfa has
been shown to affect skin, hair and eye development although the
presence of a cleft phenotype has not yet been described, and Tgfa
has been regarded thus as a modifier gene [24]. Tgfa is expressed
in a variety of developing and adult tissues and the majority of
expression studies have assayed for the presence of mRNA, the
levels of which may not correlate with the production and
processing of the protein. Alternatively, there may be physiological
redundancy among the ligands of the EGFR in some tissues. This
hypothesis has gained some validity since the demonstration by
bioinformatics approaches that the EGFR pathway contains
regions of functional redundancy in its upstream parts that may
alleviate the consequences of low EGF stimulus [50]. Although in
theory these two genes have antagonizing functions - Tgfa as a
growth factor capable of stimulating cellular proliferation and
cellular differentiation, and Irf6 as a regulator of keratinocyte
proliferation and differentiation – our biological results further
support the genetic interaction findings and warrant additional
investigations.
The data presented here together with other evidence that
suggest p63 and AP-2a cooperate to regulate IRF6 [32,51–53]
make us believe that a regulatory loop to coordinate epithelial
proliferation and differentiation exist. Disruption of this loop by
insufficient expression of TGFA, p63, AP-2a or any combination of
these genes could lead to disruption in epithelial development.
This disruption could lead to alterations such as clefts of the lip
and palate and arresting of dental development, leading to tooth
agenesis. Since TGFA, IRF6, and p63 are known to be involved in
cancer [24,54,55], and in the view of our recent findings that cleft
lip and palate families report more cancer [56–60], these gene-
gene interactions might not only explain susceptibility to oral
clefts, but also cancer.
Cleft lip/palate is a complex and heterogeneous disorder and a
likely scenario is that variation in more than one gene underlies the
isolated cleft lip/palate [61]. Additional studies should be realized
regarding IRF6-TGFA interaction in other populations and if
confirmed, these results could be used to revisit estimates of the
recurrence rates of clefting.
Table 6. Results for interaction of TGFA C3827T and IRF6
V274I marker alleles in the Brazilian Caucasian cases (N = 406)
and controls (N = 285).
TGFA rs1058213 (C3827T) IRF6 rs2235371 (V274I) P-value*
allele 1 (C) allele 2 (T)
allele 1 (C) cases 355 3 0.49
controls 256 1
allele 2 (T) cases 16 0 0
controls 15 0
allele 1 (C) allele 2 (T)
allele 1 (C) cases 327 31 0.35
controls 229 28
allele 2 (T) cases 13 3 0.08
controls 15 0
allele 1 (C) allele 2 (T)
allele 1 (C) cases 351 3 0.49
controls 255 1
allele 2 (T) cases 20 0 0
controls 16 0
allele 1 (C) allele 2 (T)
allele 1 (C) cases 325 29 0.25
controls 228 28
allele 2 (T) cases 15 5 0.03
controls 16 0
*Mantel-Haenszel test; p#0.05 indicates statistical difference (in bold).
doi:10.1371/journal.pone.0045441.t006
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Table 8. Summary of the analysis with the Latvian cases (N = 154) with cleft lip/palate and 30 case-parent trios (90 individuals)
from CEPH.
IRF6-TGFA Marker Genotypes* Expected Frequency Observed Frequency in Cleft Cases p-value
CC-CC 0.2332 0.074074 0.002
CC-CT 0.176808 0.055556 0.005
CC-TT 0.013992 0.009259 0.5
AC-CC 0.26125 0.166667 0.1
AC-CT 0.198075 0.194444 0.02
AC-TT 0.015675 0.083333 0.03
AA-CC 0.0561 0.166667 0.005
AA-CT 0.042534 0.222222 0.0000001
AA-TT 0.003366 0.027778 0.27
*The IRF6 marker used was rs2013162. The TGFA marker used was rs3732253.
doi:10.1371/journal.pone.0045441.t008
Figure 1. Loss of Tgfa expression in embryos that lack Irf6. Expression of Tgfa (A,A9), Irf6 (B, B9) and merge (C, C9) in coronal sections of E14.5
wild type murine embyos. Tgfa and Irf6 expression colocalized to oral and nasal epithelium and remaining medial edge epithelium. Magnification was
106 (A–C) and 406 (A9–C9) for boxed regions in panels A–C. No expression was observed for Tgfa and Irf6 in coronal sections of E14.5 embryos that
lack Irf6 (D). Regions of higher magnification are indicated (D9, D99). Abbreviations are palate (p), tongue (t), nasal septum (ns).
doi:10.1371/journal.pone.0045441.g001
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Materials and Methods
Subjects
The subjects of this study, their cleft subphenotypes and
characteristics of dental anomalies have been previously described
in detail [29]. Written informed consent was obtained from all
participants in the study. Parents or legal guardians provided
written consent on behalf of the minors/children participants
involved in the study. The sample consisted of 500 individuals with
clefts in treatment at the Hospital of Rehabilitation and
Craniofacial Anomalies of the University of Sa˜o Paulo, Bauru,
Brazil. Of these, 400 had cleft lip with cleft palate (168 with left
cleft lip, 154 with bilateral cleft lip, 76 with right cleft lip, and 2
median clefts), six had cleft lip only (two on the right side and four
on the left side), 66 had cleft palate only and 28 had unknown cleft
types. The control group comprised 500 healthy, non-related
individuals with no history of syndromic clefting, whom were
mostly patients and students at Bauru Dental School.
We detected evidence of confounding due to population
stratification within this Brazilian sample and therefore, for this
study, we have included only the individuals of Caucasian
ethnicity (hereby defined as Brazilians of Caucasian descent to
the third generation and without any African or Japanese descent).
Hence, 406 individuals with clefts and 285 control individuals
were included in the current analysis (Table 1).
The study was conducted with the consent of the participants
and approved by the Research and Ethics Committee of the
University of Sa˜o Paulo, Bauru and University of Pittsburgh. In
the case of children under 15 years of age, authorization was
also requested from their parents or from their legal guardian.
Buccal epithelial cells were collected from each individual as
source of genomic DNA. Procedures for buccal cell collection
and DNA extraction were performed as described elsewhere
[30,31].
Genotyping
Genotyping was performed using Taqman or SYBRH Green
chemistries (Applied Biosystems) on an automatic sequence-
detection instrument (ABI Prism 7900HT, Applied Biosystems).
Reactions were carried out with the use of standard conditions as
suggested by the manufacturer.
SNP selection was based on previous reports. Six markers were
genotyped in/nearby the IRF6 gene [6,32]. In addition, six
intragenic markers were used for TGFA [23]. Details of the
markers are presented in Table 2. For the C3296T (rs2166975)
and C3827T (rs1058213) variants in TGFA, we used allele-specific
Figure 2. Loss of Tgfa, but not Twist, expression in embryos that lack Irf6. Expression of Tgfa (A,A9), Twist (B, B9) and merge (C, C9) in coronal
sections of E13.5 wild type murine embyos. Tgfa and Twist expression colocalized to all oral epithelial surfaces of palate (p), tongue (t) and nasal
septum (ns). Magnification was 106 (A–C) and 406 (A9–C9) for boxed regions in panels A–C. No expression was observed for Tgfa in coronal sections
of E13.5 embryos that lack Irf6 (D, F), but Twist expression was not affected (E, F). Regions of higher magnification are indicated (D9–F9)).
Abbreviations are palate (p), tongue (t), nasal septum (ns).
doi:10.1371/journal.pone.0045441.g002
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primers according to previously published protocols [33]. The
primer sequences were: for C3296T, forward 59CTTATTTTCC-
CAACGTGGCC 39; reverse (for C allele),
59CTCCTCTGGGCTCTTCTG 39, reverse (for T allele),
59TCCTCCTCTGGGCTCTTCTA 39; for C3827T, forward
59CTTATTTTCCCAACGTGGCC 39; reverse (for C allele)
59CTCCTCTGGGCTCTTCTG 39, reverse (for T allele)
59TCCTCCTCTGGGCTCTTCTA 39. PCR conditions were
the same for both variants: 95uC for 10 min (1 cycle), 95uC for
15 sec, and 56uC for 40 sec (55 cycles).
Since some of these markers had not yet been previously
genotyped in Brazilians, we calculated linkage disequilibrium
between all markers using the Graphical Overview of Linkage
Disequilibrium (GOLD) software using both the squared correla-
tion coefficient (r2, above the diagonal) and Lewontin’s standard-
ized disequilibrium coefficient (D9, below the diagonal) [34]
(Table 3).
All SNP markers were first tested on a collection of samples
from the Centre d’E´tude du Polymorphisme Humain (CEPH).
Statistical Analysis
Hardy-Weinberg equilibrium and case-control
analyses. Chi-square statistics were used to assess adherence
to Hardy-Weinberg equilibrium between cases and controls.
There was no evidence of deviation from Hardy-Weinberg
equilibrium for both groups (data not shown).
For case-control comparisons in the Brazilian samples, Chi-
square test was used to assess association of markers with each cleft
subphenotype. Bonferroni correction was applied considering the
number of variables and tests performed, and P-values below
0.0002 (12 SNPs, and 17 phenotypes: 0.05/204) were considered
significant.
IRF6-TGFA interaction and attributable fraction. The
IRF6 and TGFA markers yielding the most significant associations
were used to infer the overall contribution of their interaction to
nonsyndromic cleft lip/palate in Brazilian cases and controls. We
calculated the attributable fraction (AF) for the associated IRF6
and TGFA alleles as the proportion of cleft cases in a population
that could be attributed to the interaction terms, assuming true
causality. We calculated AF = f (R-1)/R where f is the frequency
of the risk factor in the population and R is the measure of relative
risk (35). To obtain f, we used the number of cases presenting at
least one copy of overrepresented alleles compared to controls for
both markers and divided by the total number of cases. We used
the relative risk values for heritability of clefting in Brazilians in the
State of Sa˜o Paulo (RR = 4.96) as reported by Lofredo et al. [36].
We also studied three distinct data sets to replicate evidence of
interaction between IRF6 and TGFA. Genotypes available for an
additional 142 case-parent trios from ECLAMC (Latin American
Collaborative Study of Congenital Malformations) were also
included in the analysis for interaction between the IRF6 V274I
variant (rs2235371) and TGFA C3827T (rs1058213) by observing
transmission of the associated alleles at each gene from parents
heterozygous for both of the markers using the parental haplotypes
not present in the affected child as controls [37]. ECLAMC is a
hospital-based birth defects registry study that included sites in
Argentina, Bolivia, Brazil, Chile, Ecuador, Paraguay, Uruguay
and Venezuela. Genotypes and alleles at each IRF6 and TGFA
marker were tested for association with cleft lip/palate using of
Family-Based Association Test (FBAT) [38] software in the
ECLAMC cohort. The study was conducted with the consent of
the participants and approved by the Research and Ethics
Committee of the CEMIC (Centro de Educacio´n Me´dica e
Investigaciones Clı´nicas ‘‘Norberto Quirno’’), Buenos Aires,
Argentina and University of Pittsburgh. Written informed consent
was obtained from all participants in the study. Parents or legal
guardians provided written consent on behalf of the minors/
children participants involved in the study.
In addition, data from a population pool consisting of 7,047
people from family studies of CL/P sampled from Colombia,
USA, India, Spain, Philippines, China and Turkey were also
analyzed. Details regarding these are provided elsewhere [17]. In
brief, most of these families were extended multiplex kindreds, i.e.
multigenerational families with two or more affected individuals.
The phenotype was CL/P, i.e. for families to be included, it was
necessary that the proband have CL/P (i.e. no other anomalies)
and that no other family member have an indication of an
orofacial syndrome (e.g. lip pits). Each study population included
evaluations of family members by clinical geneticists to rule out
syndromic forms of CL/P. For this analysis, we considered the
per-family Z-scores for each SNP from FBAT and performed
correlation and logistic regression between each IRF6 and TGFA
SNPs to generate interaction p-values. We used the odds ratio of
the associated alleles as a measure of the relative risk in this pooled
population. The study was conducted with the consent of the
participants and approved by the Research and Ethics Committee
of the University of Pittsburgh. Written informed consent was
obtained from all participants in the study. Parents or legal
guardians provided written consent on behalf of the minors/
children participants involved in the study.
As a replication panel for these interaction analyses, we used
genotypes of 154 cases with isolated cleft lip/palate from Latvia to
test for interaction between markers in the IRF6 and TGFA genes.
Since no Latvian control samples were available, comparison data
from this analysis was drawn from genotype frequency in 30 U.S.
trios (mother/father/offspring), which were collected in 1980 from
U.S. residents with northern and western European ancestry by
the Centre d’Etude du Polymorphisme Humain (CEPH) available
at the HapMap Project (http://hapmap.ncbi.nlm.nih.gov/).
Although these control samples are presumed to be of Northern
Europe origin that is the potential that population substructures
are not matched in this set of cases and controls. We did the same
calculations used for the Brazilian and ECLAMC datasets. To
obtain f, we used the frequency of the over-represented haplotype
among the CEPH controls. We used a relative risk value of 1.0 in
the Latvians due to the very high frequency of maternal smoking
in the population (67% to 81%) as reported by Patla et al. [39].
Maternal smoking is known to increase the susceptibility to clefts
approximately 1.5 times [61] and in a population that have a
frequency of smokers as high as the Latvians, we decided that
would be appropriate to not input relative risk values higher than
1.0 for this calculation. The study was conducted with the consent
of the participants and approved by the Research and Ethics
Committee of the Riga Stradins University and University of
Pittsburgh. Written informed consent was obtained from all
participants in the study. Parents or legal guardians provided
written consent on behalf of the minors/children participants
involved in the study.
Overall, 8,717 individuals were used in this test of interaction
between IRF6 and TGFA.
Fluorescent Immunostaining
Expression of Tgfa and Irf6 proteins was performed on paraffin
sections from heads of wild type and Irf6 null embryos at E13.5
and 14.5. Maintenance and handling of mice were approved by
the Animal Care Unit at Michigan State University. Tissues were
deparaffinized and rehydrated in a series of ethanol dilutions.
Slides were boiled for 5 min in 0.08% saponin in BPS for antigen
IRF6-TGFA Interaction and Clefts
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retrieval. Sections were blocked with 10% normal goat serum in
1% PBS-BSA for 1 hr, then incubated overnight at 4 sˇC with the
following primary antibodies: monoclonal mouse anti-Tgfa (1:150,
clone 213-4.4, GeneTex, Irvine, CA) and polyclonal rabbit anti-
Irf6 (1:500, Irf6-SPEA). After rinsing in PBS, sections were
incubated with secondary antibodies conjugated to Alexa Fluor-
ophore 488 or 555 (Molecular Probes, Invitrogen, CA). The nuclei
were counterstained with DAPI in PBS (1:1000). The images were
taken using a Nikon Eclipse 90i fluorescent microscope.
To investigate if Tgfa was influenced by Irf6, we also investigated
Tgfa expression in the Irf6 knockout mice generated by Ingraham
et al. [40] using the methods and reagents as described above.
Skin tissue sections were used as positive controls for Tgfa [41]
and Irf6 [40]. To confirm the specificity of the immunostaining,
primary antibodies were substituted with PBS (for Tgfa) and
normal rabbit serum (for Irf6). No immunoreactivity was detected
in any of the negative control sections.
Supporting Information
Table S1 Genotyping data of ECLAMC cleft lip and palate
trios.
(PDF)
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